A
Aslan Aygun
Researcher at Istanbul University
Publications - 9
Citations - 401
Aslan Aygun is an academic researcher from Istanbul University. The author has contributed to research in topics: Prostate cancer & Positron emission tomography. The author has an hindex of 6, co-authored 9 publications receiving 332 citations.
Papers
More filters
Journal ArticleDOI
Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Levent Kabasakal,Mohammad Abuqbeitah,Aslan Aygun,Nami Yeyin,Meltem Ocak,Emre Demirci,Türkay Toklu +6 more
TL;DR: Estimating the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of 177Lu-labeled PSMA ligand suggested that 177 Lu-PSMA-617 therapy seems to be a safe method and the dose-limiting organ seems to been the parotid glands rather than kidneys and bone marrow.
Journal ArticleDOI
Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Levent Kabasakal,Emre Demirci,Meltem Ocak,Reşit Akyel,Jamal Nematyazar,Aslan Aygun,Metin Halac,Zübeyi̇r Talat,Ahmet Araman +8 more
TL;DR: PSMA PET/CT imaging seems to be a valuable imaging modality for evaluation of primary prostate cancer and it seems to have potential for the detection of lymph node and bone metastases.
Journal ArticleDOI
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.
Levent Kabasakal,Türkay Toklu,Nami Yeyin,Emre Demirci,Mohammad Abuqbeitah,Meltem Ocak,Aslan Aygun,Emre Karayel,Huseyin Pehlivanoglu,Nalan Alan Selçuk +9 more
TL;DR: Lu-177-PSMA-617 therapy seems to be a safe method for the treatment of castration-resistant prostate cancer patients and is a highly stable compound both in vitro and in vivo.
Journal ArticleDOI
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Levent Kabasakal,Emre Demirci,Jamal Nematyazar,Reşit Akyel,Baresh Razavi,Meltem Ocak,Aslan Aygun,Can Obek,Ali Riza Kural +8 more
TL;DR: PET/CT with 68Ga-PSMA is a valuable tool for assessing recurrence of PCa with a high sensitivity in patients who have PSA levels between 0.2 and 5 ng/ml, and it is suggested that PSMA PET/CT can be used in patients with very low but increasing PSA Levels, which, in many cases, may influence further clinical management.
Journal ArticleDOI
Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
Meltem Ocak,Emre Demirci,Levent Kabasakal,Aslan Aygun,Rumeysa Tutar,Ahmet Araman,Bedii Kanmaz +6 more
TL;DR: It is suggested that Ga-68 DOTA-TATE has a higher lesion uptake even in WDTC patients and may have potential advantage over Ga- 68 Dota-NOC.